| Biotechnology Industry | Healthcare Sector | - CEO | LSE Exchange | GB00BNRRP542 ISIN |
| United Kingdom Country | 37 Employees | - Last Dividend | - Last Split | - IPO Date |
Aptamer Group plc is a pioneering company located in York, United Kingdom, recognized for its innovative work in the field of research, diagnostics, and therapeutics. Since its establishment in 2008, Aptamer Group has been dedicated to providing cutting-edge solutions globally, including in the United Kingdom and the rest of Europe. The company has carved a niche for itself by specializing in the development and application of oligonucleotide binders. Aptamer Group plc has cemented its reputation by servicing a wide range of clients, including leading pharmaceutical companies, developmental companies focusing on diagnostics, and various research institutes. Its services are tailored to meet the evolving demands of bioprocessing, diagnostic, and pharmaceutical scientists, leveraging the company’s proprietary Optimer platform for the discovery and development of oligonucleotide binders.
This flagship technology platform facilitates the discovery and development of oligonucleotide binders, known as Optimers. The Optimer platform stands out for its ability to yield high-affinity and specific nucleic acid-based aptamers, which are employed in various research and therapeutic applications. This platform underscores Aptamer Group's commitment to innovation in the life sciences sector.
Aptamer Group offers bespoke service packages for the development of customized oligonucleotide-based aptamer and Optimer binders. These personalized solutions cater to specific client needs, targeting a wide range of applications from diagnostics to therapy. The flexibility and adaptability of these services make them highly valuable to clients working in complex and diverse scientific fields.
The company delivers a suite of solutions tailored to the needs of bioprocessing, diagnostic, and pharmaceutical scientists. These solutions encompass a variety of applications, including but not limited to, therapeutic drug monitoring, biomarker discovery, and molecular diagnostics. Aptamer Group leverages its expertise to provide innovative and reliable solutions that advance scientific research and development.
Aptamer Group extends its comprehensive expertise through contract research services, particularly focusing on the therapeutics domain. These services enable clients to navigate the complexities of therapeutic development with the support of a seasoned partner. By offering such services, Aptamer Group plays a crucial role in accelerating the pace of new therapeutic discoveries and their subsequent development.